ZBRA — Zebra Technologies Corporation

The tape and the sell-side are both leaning positive after the August 4, 2026 print: Q2 2026 adjusted EPS of $6.35 crushed ~$4.35 consensus, revenue rose ~20% YoY to $1.557B, and management raised FY2026 non-GAAP EPS guidance to $20.75-$21.25 from $18.30-$18.70, triggering a >20% single-session rally and target hikes from BNP Paribas ($455), KeyBanc ($430), Barclays and Needham ($410). The ratings breakdown (19 buy, 8 hold, 0 sell) confirms the bullish tilt, and management explicitly framed memory-chip supply, not demand, as the binding constraint on upside. Two caveats temper this: the stock is still 7.4% below where it sat a month ago as of 2026-09-13, and FMP's stored consensus target of $363.67 (7 analysts) looks stale next to the post-Q2 revisions - the honest read is a hot narrative that has already been partly paid for.

This is a genuine cyclical inflection, not a blip. Revenue went $956M (Q3'23) -> $1,009M -> $1,175M -> $1,217M -> $1,255M -> $1,334M -> $1,308M -> $1,293M -> $1,320M -> $1,475M -> $1,495M -> $1,557M (Q2'26), with YoY growth accelerating every quarter from +5.2% (Q3'25) to +6.2% (Q2'25) to +11.3% (Q1'25) to +10.6% (Q4'25) to +14.3% (Q1'26) to +20.4% (Q2'26). Margins tell the same story: operating margin went from -1.3% in Q3'23 and 7.3% in Q4'23 to a 13.5-15.2% band through 2024, then 13.9-15.1% through mid-2025, and has now inflected to 20.6% in Q2'26 ($321M operating income on $1,557M revenue) with gross margin at 53.0%. Two anomalies deserve flagging: Q4'25 gross margin dipped to 44.6% and net income was only $70M against $222M of operating income (vs $163M net on $225M operating in Q4'24), implying a discrete non-operating or tax charge that quarter. Cash generation is solid but less explosive than the headline: TTM FCF through 2026-07-04 is $904M ($198M + $163M + $327M + $216M), up roughly 6% YoY, helped by unusually light capex of just $13M per quarter in each of the last two periods.

It depends entirely on which earnings you use, and the gap is unusually wide. As of 2026-09-13, the $350.37 price on $10.703 of TTM GAAP EPS gives a 32.8x P/E and a meaningless 116x PEG; on the FY2026 non-GAAP guidance midpoint of ~$21.00 the forward P/E is 16.7x, and on FMP's $21.125 next-FY consensus it is 16.6x. Against its own history, that is undemanding - the 5-year average P/E is 36.3x (though that average is built on the 2023-24 earnings trough) and the 5-year average P/S is 3.46x versus 2.85x today, which is why the deterministic model tags it 'Cheap vs. its own history' (reference score 67.0). On the other side, P/B of 5.14x and EV/EBITDA of 17.9x are not cheap in absolute terms, and $904M TTM FCF on a $16.7B market cap is a 5.4% yield - decent, not compelling. My read: fair-to-modestly-cheap on forward non-GAAP earnings, contingent on a back-half EPS delivery that has not happened yet.

The market has already paid for the inflection - the stock is up 72.8% in six months as of 2026-09-13 - but it has not overpaid on forward numbers. At 16.6x FY2026E non-GAAP EPS, ZBRA is pricing in something like mid-single-digit-to-low-double-digit EPS growth, not the 20% revenue growth the last quarter actually delivered. The gap to watch is GAAP vs adjusted: Q2'26 GAAP diluted EPS was $4.60 against $6.35 adjusted, and TTM GAAP EPS of $10.70 sits far below the ~$21 forward figure, so a large chunk of the 'earnings power' story rests on amortization/SBC/one-off add-backs. Roughly $11 of the $21 FY2026 estimate has to land in the second half. If Q3 validates that and memory supply eases, 17-18x forward is defensible and the stock can grind higher; if the company only hits the low end of guidance or component constraints persist into 2027, the multiple compresses toward 14x, which is roughly $295-300 on FY2026 numbers. The setup is asymmetric but no longer cheap enough to be forgiving.

As of 2026-09-13, RSI(14) sat at 52.6 - dead-neutral, neither overbought nor oversold - after a -3.41% week and -7.4% month, meaning the August melt-up has cooled without breaking trend. Price was 2.12% below its 20-day SMA (implied ~$358), 8.84% above its 50-day (~$322) and 34.99% above its 200-day (~$260). That 35% extension above the 200-day is the real timing risk: the 52-week high of $386.23 is overhead resistance and the stock is nearly 9% off it. The constructive read is a consolidation inside a strong uptrend with the 20-day offering first support and the 50-day (~$322) as the more meaningful entry level; the cautionary read is that momentum names 35% above the 200-day frequently mean-revert before they re-accelerate. This is a stock to accumulate on weakness toward $320-330, not to chase at $350 after a 73% six-month run.

• Memory-chip and component shortage: management named this as the explicit ceiling on revenue upside, which means some demand is being deferred rather than lost - bullish if supply normalizes in 2027, bearish if it drags revenue timing and inflates input costs.
• Enterprise capex scrutiny under elevated rates: mission-critical automation projects with fast paybacks are still getting funded, but a broad capex air pocket in retail/manufacturing/logistics would hit ZBRA's hardware volumes quickly.
• Structural automation and 'Physical AI' adoption at the edge: retail, warehouse, manufacturing and healthcare spending on workflow automation and asset tracking remains a multi-year tailwind that Zebra sits directly in front of.
• Tariffs, trade policy and global sourcing: Zebra manufactures and sources across multiple geographies, so component cost inflation and tariff shifts flow straight into the 49-53% gross margin line.
• End-market cyclicality in retail and logistics: ZBRA's 2023 experience (revenue ~$956M in a quarter, negative operating margin) shows how fast AIDC demand can stall when warehouse and retail capex pauses.
• M&A integration and balance-sheet optics: the Elo Touch acquisition added revenue and amortization, and in Q2'26 long-term debt fell from $2.387B to $0.493B while current liabilities jumped from $1.763B to $3.998B - roughly $1.9B of debt moving into current maturities, which shifts the near-term refinancing conversation.

• Q3 2026 earnings in early November 2026 (estimated Nov 2-3): the key test of whether H2 EPS delivers the roughly $11 needed to hit the $20.75-$21.25 guidance range, plus any update on memory-chip mitigation and supply agreements.
• Evidence of component supply easing into 2027 - management says demand exceeds supply today, so any unclogging unlocks revenue the current guidance does not appear to capture.
• Further sell-side target revisions after Q3 (BNP at $455, KeyBanc at $430, Barclays/Needham at $410 currently sit well above FMP's stale $363.67 consensus) which can pull the multiple higher.
• FY2027 guidance, typically issued with Q4 results in February, that would show whether the $21 base grows toward the mid-$20s or plateaus.
• Refinancing of the roughly $1.9B of debt now classified as current, and any further M&A or Elo Touch integration milestones.
• Continued adoption of workflow automation and edge/'Physical AI' deployments across retail, manufacturing, transportation, logistics and healthcare.

• The memory-chip bottleneck is the biggest single risk: it is currently capping revenue, and if it persists into 2027 it converts a demand story into a supply story and pressures the margin expansion the stock was re-rated on.
• Technical extension: at $350.37 on 2026-09-13 the stock sat 34.99% above its 200-day SMA and 72.8% above its level six months earlier, leaving it vulnerable to a sharp mean-reversion move if any quarter disappoints.
• Earnings quality: Q2'26 GAAP EPS of $4.60 versus $6.35 adjusted, TTM GAAP EPS of $10.70 against a ~$21 forward estimate, and a Q4'25 quarter where net income of $70M came in $152M below operating income - the 'adjusted' earnings base carries a lot of add-backs and one-off items.
• Liquidity optics and refinancing: with $0.157B of cash against $2.062B of current assets and $3.998B of current liabilities (current ratio 0.516, quick ratio 0.332) after the debt reclassification, the company needs to term out roughly $1.9B of maturities into a favorable credit market.
• Cyclicality is real, not theoretical: revenue was $956M in a quarter and operating margin was negative as recently as late 2023; a repeat AIDC demand pause would hit EPS fast given the operating leverage that is currently working in the company's favor.
• Valuation support is largely relative: the 'cheap vs. its own history' signal rests on a 5-year average P/E of 36.3x that was itself distorted by trough earnings in 2023-24, so it is a weaker anchor than it appears.

Zebra is in a real, evidence-backed cyclical upturn - revenue growth accelerated from +5.2% YoY in Q3'25 to +20.4% in Q2'26, operating margin reached 20.6%, and management raised FY2026 EPS guidance by roughly 13% in August 2026. At $350.37 on 2026-09-13 the stock trades at ~16.6x forward non-GAAP EPS, which is not expensive for that trajectory, but the market has already banked a 73% six-month gain and the shares sit 35% above the 200-day SMA with a large GAAP-to-adjusted earnings gap and a memory-chip ceiling on revenue. My honest read: a good business in a good part of its cycle, but the entry point matters more than the story here - own it on pullbacks toward the 50-day (~$322) rather than chasing at $350, and treat the early-November Q3 print as the real referendum on the H2 earnings bridge.

Blended forward earnings-and-cash approach: 17.5x a blended forward non-GAAP EPS of roughly $22.20 (FY2026E $21.13, matching the raised guidance midpoint and consensus; FY2027E ~$23.50 at ~11% growth) yields ~$388. Cross-check: ~$1.0B of forward free cash flow on 47.6M diluted shares at a 5.4% required FCF yield also implies ~$389 per share, so the two independent methods converge on the same figure as of 2026-09-13. The 17.5x multiple is justified as a modest premium to the ~16.6x the stock trades at today on the same forward EPS, given 20% revenue growth and 20%+ operating margins, but below the 20-25x forward multiples ZBRA commanded in prior growth cycles because of the memory-supply cap, the GAAP/adjusted earnings gap, and the hardware cyclicality.